Tag: 200-300

On June 25, 2015, Stockwell, Brent R.; Welsch, Matthew; Yang, Wan Seok published a patent.Application In Synthesis of 5-Bromo-2-isopropoxyaniline The title of the patent was Quinazolinone-based oncogenic-ras-selective lethal compounds and their use. And the patent contained the following:

The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided. The experimental process involved the reaction of 5-Bromo-2-isopropoxyaniline(cas: 1019442-22-8).Application In Synthesis of 5-Bromo-2-isopropoxyaniline

The Article related to antitumor quinazolinone preparation oncogenic ras mutation cancer therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 5-Bromo-2-isopropoxyaniline

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On January 16, 2014, Stockwell, Brent R.; Welsch, Matthew; Yang, Wan Seok published a patent.HPLC of Formula: 1019442-22-8 The title of the patent was Quinazolinone-based oncogenic-ras-selective lethal compounds and their use. And the patent contained the following:

The present invention provides compounds for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided. The experimental process involved the reaction of 5-Bromo-2-isopropoxyaniline(cas: 1019442-22-8).HPLC of Formula: 1019442-22-8

The Article related to antitumor quinazolinone preparation oncogenic ras mutation cancer therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.HPLC of Formula: 1019442-22-8

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Lien, Vegard Torp; Kristiansen, Margrethe Konstanse; Pettersen, Solveig; Haugen, Mads Haugland; Olberg, Dag Erlend; Waaler, Jo; Klaveness, Jo published an article in 2019, the title of the article was Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation.Safety of 2-(2-Bromoethyl)isoindoline-1,3-dione And the article contains the following content:

Both the kinase MET and the WNT signaling pathway are attractive targets in cancer therapy, and synergistic effects have previously been observed in animal models upon simultaneous inhibition. A strategy towards a designed multiple ligand of MET and WNT signaling is pursued based on the two hetero biaryl systems present in both the MET inhibitor tepotinib and WNT signaling inhibitor TC-E 5001. Initial screening was conducted to find the most suitable ring systems for further optimization, whereas a second screen explored modifications towards pyridazinones and triazolo pyridazines. Up to 54% reduction of WNT signaling activity at 10 microM concentration was achieved, however, only low affinities towards MET were observed Overall, the thiophene substituted pyridazinone 40 was the best dual MET and WNT signaling inhibitor, with a 17% and 19% reduction of activity, resp. Although further optimizations are needed to achieve more potent dual inhibitors, the strategy presented herein can be valuable towards the development of a dual inhibitor of MET and WNT signaling. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Safety of 2-(2-Bromoethyl)isoindoline-1,3-dione

The Article related to met kinase wnt inhibitor anticancer agent signaling, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Safety of 2-(2-Bromoethyl)isoindoline-1,3-dione

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On February 15, 2021, Yang, Ling; Tan, Dong-Hang; Fan, Wen-Xin; Liu, Xu-Ge; Wu, Jia-Qiang; Huang, Zhi-Shu; Li, Qingjiang; Wang, Honggen published an article.Safety of 4-(Bromomethyl)-1,1′-biphenyl The title of the article was Photochemical Radical C-H Halogenation of Benzyl N-Methyliminodiacetyl (MIDA) Boronates: Synthesis of α-Functionalized Alkyl Boronates. And the article contained the following:

Benzylboronates ArCH2B(MIDA) were halogenated in α-position by reaction with NBS either initiated with benzyl peroxide or photochem., giving α-haloboronates ArCHXB(MIDA). Fluorination and chlorination were performed by reactions with Selectfluor and NCS, resp., under 9-fluorenone catalysis. α-Haloboronates are useful organic synthons that can be converted to a diverse array of α-substituted alkyl borons. Methods to α-haloboronates are limiting and often suffer from harsh reaction conditions. Reported herein is a photochem. radical C-H halogenation of benzyl N-methyliminodiacetyl (MIDA) boronates. Fluorination, chlorination, and bromination reactions were effective by using this protocol. Upon reaction with different nucleophiles, the C-Br bond in the brominated product could be readily transformed to a series of C-C, C-O, C-N, C-S, C-P, and C-I bonds, some of which are difficult to forge with α-halo sp2-B boronate esters. An activation effect of B(MIDA) moiety was found. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Safety of 4-(Bromomethyl)-1,1′-biphenyl

The Article related to bmida methyliminodiacetyl boronate photochem halogenation preparation haloboronate, halogenation, ketone catalysis, organoboron, photochemistry, radical reaction, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Safety of 4-(Bromomethyl)-1,1′-biphenyl

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 25, 2022, Yang, Xiaoxu; Ge, Shaozhong published an article.Product Details of 2567-29-5 The title of the article was Cobalt-Catalyzed 1,1,3-Triborylation of Terminal Alkynes. And the article contained the following:

The authors have developed a Co-catalyzed regioselective 1,1,3-triborylation reaction of terminal alkynes with pinacolborane (HBpin) with a catalyst generated in situ from readily available and bench-stable Co(acac)2 and xantphos. A variety of terminal alkynes undergo this triborylation reaction, affording the corresponding 1,1,3-triborylalkanes in good yields with high selectivity. The synthetic utility of this catalytic protocol was demonstrated by developing selective stepwise functionalization of 1,1,3-triborylalkane products. The results of mechanistic studies, such as conducting control experiments and D-labeling reactions, monitoring the reaction process, and identifying reaction intermediates, suggest that this 1,1,3-triborylation reaction proceeds through 1,3-diborylation of alken-1-ylboronates formed by Co-catalyzed hydroboration of terminal alkynes. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Product Details of 2567-29-5

The Article related to terminal alkyne preparation cobalt catalyzed triborylation pinacolborane, triborylalkane preparation reactivity, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Product Details of 2567-29-5

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On May 29, 2018, Zhu, Bin published a patent.Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene The title of the patent was Microglial cell IL-1β secretion inhibitor, and its preparation method and application in treatment of neuroinflammatory diseases. And the patent contained the following:

The title microglial cell IL-1β secretion inhibitor is (((2,5-dibromocyclopenta-2,4-diene-1,1-diyl)bis(methylene))bis(6-alkyl-3,1-phenylene))diboronic acid, has structural formula shown as formula I in Claim 1, wherein R is C1-C10 alkyl or C3-C8 cycloalkyl. The invention also provides preparation method of above compound from cyclopenta-1,3-diene, 2-bromo-4-(bromomethyl)-1-alkylbenzene, boric acid, and bromine. The invention also provides application of the microglial cell IL-1β secretion inhibitor in preparation of drugs for treatment of neuroinflammatory diseases. The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene

The Article related to bromocyclopenta dienediyl diboronic acid preparation neuroinflammatory disease treatment, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On June 23, 2022, Long, Alan; Liu, Chun Yu; Liu, Chunliang; Zhou, Yasheen; Pulley, Shon R.; Graham, Keith Andrew Newton published a patent.Product Details of 1160653-94-0 The title of the patent was Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof. And the patent contained the following:

The present invention describes novel boron containing pyrazole compounds, e.g. I, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described. The experimental process involved the reaction of 3-Bromo-2-fluoro-6-methoxybenzaldehyde(cas: 1160653-94-0).Product Details of 1160653-94-0

The Article related to boron amidopyrazole preparation janus kinase inhibition autoimmune anticancer, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Product Details of 1160653-94-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 1, 2020, Kubasov, A. S.; Turishev, E. S.; Golubev, A. V.; Bykov, A. Yu.; Zhizhin, K. Yu.; Kuznetsov, N. T. published an article.Synthetic Route of 574-98-1 The title of the article was The method for synthesis of 2-sulfonium closo-decaborate anions derivatives with exo-polyhedral aminogroups. And the article contained the following:

A method for the preparation of sulfonium derivatives of the closo-decaborate anion with the exo-polyhedral amino groups [B10H9S((CH2)nNH2)2]- (n = 1-3) has been developed. The method is based on the alkylation of the [B10H9SH]2- anion with N-bromoalkyl phthalimides and subsequent removal of the phthalimide protection with hydrazine. We could show that the interaction between the [B10H9SH]2- anion with bromomethyl phthalimide groups allowed us to prepare selectively mono-S-substituted sulfanyl derivatives [B10H9SCH2N(CO)2C6H4]2-. Due to the high stability of the sulfonium derivatives of the closo-decaborate anion, it is possible to obtain perchlorinated analogs of these compounds by chlorination of the salts n-Bu4N[B10H9S((CH2)nN(CO)2C6H4)2] (n = 1-3) with sulfuryl chloride in acetonitrile. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Synthetic Route of 574-98-1

The Article related to crystal structure mol sulfonium decaborate anion polyhedral amino preparation, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Synthetic Route of 574-98-1

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 21, 2022, Yang, Dun; Zhang, Jing; Zhang, Shenqiu; Allen, Thaddeus; Shi, Qiong; Nimishetti, Naganna; Huang, Jian; Li, Hongmei; Yang, Chenglu published a patent.Related Products of 259231-26-0 The title of the patent was Preparation of fused azepine compounds and their use in the treatment of cancer. And the patent contained the following:

The invention relates to fused azepines of formula I and pharmaceutically acceptable salts thereof; their preparation and use in the treatment of cancer. Compounds of formula I, wherein X is O and S; ring A is (un)substituted Ph, (un)substituted 6-membered heteroaryl; L is a bond, CO, SO2, etc.; each R1 is independently halo, CN, (un)substituted Ph, etc.; each R2 is H, CN, (un)substituted Ph, etc.; each R3 is (un)substituted Ph, (un)substituted heteroaryl, (un)substituted 3- to 7-membered carbocyclyl, etc.; m = 0 – 4; p = 0 – 5; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by condensation of Me 5-hydroxy-2-oxo-2,3-dihydro-1H-benzo[b]azepine-4-carboxylate with (bromomethyl)benzene. The invention compounds were evaluated for their anticancer activities (some data given). The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).Related Products of 259231-26-0

The Article related to fused azepine treatment cancer preparation, Heterocyclic Compounds (One Hetero Atom): Higher-Membered Rings and other aspects.Related Products of 259231-26-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On May 13, 2004, Bit, Rino Antonio; Giblin, Gerard Martin Paul; Hall, Adrian; Hurst, David Nigel; Kilford, Ian Reginald; Miller, Neil Derek; Scoccitti, Tiziana published a patent.Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate The title of the patent was Preparation of benzoic acids and related compounds as EP1 receptor antagonists for the treatment of prostaglandin mediated diseases.. And the patent contained the following:

Title compounds I [A = (un)substituted aryl, 5 or 6-membered heterocyclyl ring, bicyclic heterocyclyl; B = Ph, pyridyl; Z = O, S, SO, etc.; R1 = CO2R4, CN, CONR5R6, etc.; R2a, R2b = H, halogen, (un)substituted alkyl, etc.; Rx = (un)substituted alkyl, CQaQb-heterocyclyl, CQaQb-bicyclic heterocyclyl, etc.; R4, R5 = H, (un)substituted alkyl; R6 = H, (un)substituted alkyl, heteroaryl, etc.; R8, R9 = H, Cl, F, etc.; Qa, Qb = H, CH3] and their pharmaceutically acceptable derivatives were prepared For example, the Suzuki coupling of Et 2′-bromobiphenyl-3-carboxylate and 2-benzyloxy-5-chlorophenylboronic acid, e.g., prepared from 3-ethoxycarbonylphenylboronic acid, followed by hydrolysis afforded compound I [A-R1 = 3-carboxyphenyl; Z = O; R2a = H, R2b = 5-Cl; R8, R9 = H] in 39% overall yield. In human prostanoid EP1 receptor binding assays, 90-examples of compounds I exhibited pIC50 values ranging from 6.0->9.0 at the EP1 receptor and pIC50 values of <6.0 at the EP3 receptor. Of note, no toxicol. effects are indicated/expected (sic) when the compounds I are administered at the assay concentration of 3 nM. Compounds I are claimed useful for the treatment of prostaglandin mediated diseases, e.g., inflammation, pain, etc. The experimental process involved the reaction of Ethyl 2-bromo-6-fluorobenzoate(cas: 1214362-62-5).Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate

The Article related to benzoic acid derivative preparation ep1 receptor antagonist prostaglandin disease, antiinflammatory agent benzoic acid derivative preparation ep1 receptor antagonist, analgesic benzoic acid derivative preparation ep1 receptor antagonist and other aspects.Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary